Eric Steffe was named the 2018 “Patent Strategy & Management Attorney of the Year – District of Columbia” by LMG Life Sciences.

Overview

Eric K. Steffe is a director in Sterne Kessler’s Biotechnology & Chemical Practice Group. Eric’s practice involves providing strategic counsel to his clients in various areas of patent law, with special emphasis on therapeutic antibodies, gene therapies, CRISPR, vaccines, diagnostics, antisense technologies, personalized medicine, and cell culturing/bioprocessing methods.

Eric has extensive expertise in inter partes review proceedings, patent reexaminations, managing complicated multi-family patent portfolios protecting pipeline and FDA-approved biotech products, preserving freedom to operate, interferences, and the IP issues arising out of industry collaborations and ongoing research. Additionally, his practice includes providing strategic advice to numerous companies seeking to launch products. Eric has published and lectured extensively in the field, testified before Congress as a legal expert regarding the Cooperative Research and Technology Enhancement (CREATE) Act.

The Legal 500 has recognized Eric five times as a “Leading Lawyer” in the U.S. for his patent prosecution work; a distinction awarded to only ten other attorneys in the entire country. He was awarded the LMG Life Sciences, “Patent Strategy & Management Attorney of the Year – District of Columbia” in 2018 and has been an LMG Life Sciences Star since 2017. Further recognition includes being named an IAM Patent 1000 leading practitioner for patent prosecution since 2014 and rankings in the Who’s Who Legal guide for patents since 2016.

Eric was previously the chairperson of the firm’s Patent Prosecution Practice and developed the concept for the firm’s popular publication the “Patent Prosecution Toolkit” for which he was the inaugural editor and author of several chapters.

Eric received his J.D. from George Mason University School of Law, his M.S. in molecular genetics, and his B.S. in physics from the University of Georgia.

Accolades

  • IAM Patent 1000, “Washington, D.C.: Recommended – Patent Prosecution” (2023 – 2014)
  • Who’s Who Legal, “IP – Patents” (2023 – 2016)
  • LMG Life Sciences, “Life Sciences Star” (2023 – 2017)
  • The Legal 500, “Leading Lawyer in Intellectual Property – Patent Prosecution: Utility and Design Patents” (2019 – 2015)
  • Managing IP, “IP Star” (2023 – 2019)
  • LMG Life Sciences, “Patent Strategy & Management Attorney of the Year – District of Columbia” (2018)
  • LMG Life Sciences, “Finalist – Patent Strategy & Management Attorney of the Year – District of Columbia” (2019)

Education

  • J.D., George Mason University Antonin Scalia Law School
  • M.S., Molecular Genetics, University of Georgia
  • B.S., Physics, University of Georgia

Admissions

  • District of Columbia
  • United States Patent & Trademark Office

Related Resources From Eric K. Steffe

In the News Bristol-Myers To Buy Orum's Cancer Treatment Program Law360 November 6, 2023
Press Release LMG Life Sciences Ranks Sterne Kessler and Seven Directors for Patent Litigation and Prosecution Sterne, Kessler, Goldstein & Fox September 21, 2023
Press Release Six Sterne Kessler Directors Ranked in Who’s Who Legal: IP 2023 Global Guide Sterne, Kessler, Goldstein & Fox August 11, 2023
In the News Korean Co. Can't Be First To Invent CRISPR, PTAB Told Law360 September 12, 2022
Press Release Five Sterne Kessler Directors Named in 2022 Who’s Who Legal Guides Sterne, Kessler, Goldstein & Fox July 26, 2022
In the News ImmunoGen Patent Application Suit Sent Back to Court (1) Bloomberg Law March 25, 2022
Press Release Sterne Kessler and Seven Directors Earn Top-Tier Designations in 2021 LMG Life Sciences Rankings Sterne, Kessler, Goldstein & Fox September 29, 2021
Press Release Four Sterne Kessler Directors Named in 2021 Who’s Who Legal Guides Sterne, Kessler, Goldstein & Fox July 31, 2021
Press Release Sterne Kessler Client Wins 2020 Nobel Prize in Chemistry for CRISPR-Cas9 Technology Sterne, Kessler, Goldstein & Fox P.L.L.C. October 8, 2020
Press Release Firm and Seven Directors Recognized in 2020 LMG Life Sciences Rankings Sterne, Kessler, Goldstein & Fox P.L.L.C. October 6, 2020
In the News In Case You Missed It: Hottest Firms And Stories On Law360 Law360 September 11, 2020
Press Release Sterne, Kessler, Goldstein & Fox and 15 Directors Earn Top Rankings in IAM Patent 1000 Sterne, Kessler, Goldstein & Fox P.L.L.C. June 16, 2020
Press Release Sterne Kessler Ranked and 13 Directors Named “IP Stars” by Managing Intellectual Property Sterne, Kessler, Goldstein & Fox P.L.L.C. May 5, 2020
Press Release Director Eldora L. Ellison, Ph.D. Receives Top Honor at 2019 LMG Life Sciences Awards Sterne, Kessler, Goldstein & Fox P.L.L.C September 23, 2019
Press Release Sterne Kessler Prominent Again in Intellectual Asset Management Magazine’s "IAM Patent 1000" Sterne, Kessler, Goldstein & Fox P.L.L.C June 12, 2019
Press Release Sterne Kessler Recognized as a “Top Tier” Firm by Legal 500 for Excellence in IP Sterne, Kessler, Goldstein & Fox June 4, 2019
In the News University Of California Gets 5th CRISPR Patent Law360 May 29, 2019
Press Release Sterne Kessler Recognized By LMG Life Sciences Among The Top IP Firms and Attorneys Sterne, Kessler, Goldstein & Fox September 25, 2018
In the News How To Prepare Patents That Can Survive AIA Reviews Law360 November 15, 2016
News Praxair Distribution, Inc. v. Ino Therapeutics (PTAB Aug. 25, 2016) Federal Circuit Bar Association Reviewed Adjudicators Digest September 1, 2016
In the News ImmunoGen Cancer Patent Still Valid After Phigenix's Dispute Bloomberg BNA October 29, 2015
In the News PTAB Upholds ImmunoGen’s Breast Cancer Drug Patent Law360 October 28, 2015